BioSpace News Archive

Business

Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab

Humanigen, Inc. have received approval from South Korea’s MFDS (the South Korean equivalent of the U.S. FDA) to conduct a Phase 1 clinical study of lenzilumab, which may support potential use in the treatment of hospitalized COVID-19 patients.

July 22, 2021
·
6 min read
Menopause Market SWOT Analysis by Top Vendors and Forecast Research to 2028

The “Global Menopause Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis.

July 22, 2021
·
4 min read
Business

Awakn Life Sciences Announces the Addition of Renowned Substance Addiction Researcher Professor Barbara Mason to Its Clinical Advisory Board

The board, which is chaired by Prof. David Nutt is focused on bringing new therapeutic paradigms to market as quickly as possible.

July 22, 2021
·
6 min read
Drug Development

Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients

Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the publication of a post-hoc analysis of its successful Phase 2b knee osteoarthritis clinical trial in Rheumatology and Therapy.

July 22, 2021
·
2 min read
Therma Bright Awaits FDA-EUA Approval From Over 260 AcuVid(TM) Clinical Study Test Results

In total, 264 individuals were enrolled in the study with duration of symptoms that ranged from one (1) day to more than 10 days.

July 22, 2021
·
8 min read
Business

Agilent Technologies Celebrates More than 20 Years of Sustainable Progress

Agilent Technologies, Inc. (NYSE: A) today issued its 21 st annual Corporate Social Responsibility (CSR) report .

July 22, 2021
·
3 min read
Foresight Diagnostics’ PhasED-Seq Circulating Tumor DNA Platform Demonstrates Highly Sensitive Minimal Residual Disease (MRD) Detection in B-Cell Lymphomas

Foresight Diagnostics today announced publication of studies demonstrating unprecedented analytical and clinical sensitivity of the Company’s proprietary circulating tumor DNA (ctDNA) detection platform for minimal residual disease (MRD) detection in B-cell lymphomas

July 22, 2021
·
6 min read
Biotech Bay

“Promising development in the fight with cancer using artificial intelligence” with a new privacy-preserving approach named MEDomics

Published first in Nature Cancer, “MEDomics” refers to a novel approach using hospital based medical notes to refine predictions and prognosis in cancer patients over time.

July 22, 2021
·
2 min read
Genetown

Synlogic Publishes Papers in Nature Journals Demonstrating Proof-of-Mechanism and Potential of Synthetic Biotic Platform for the Treatment of Phenylketonuria (PKU)

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today the publication of two papers in the journals Nature Metabolism and Communications Biology.

July 22, 2021
·
6 min read
Biotech Beach

Gigadock™ Functionality in Orion™ Molecular Design Platform Rapidly Identifies Novel Chemical Entities for GPCR Targets

OpenEye Scientific and Beacon Discovery today announced the rapid identification of two novel chemical entities and more than 30 potent hits for known G-Protein Coupled Receptor (GPCR) targets using Gigadock™ functionality in OpenEye’s Orion™ molecular design cloud platform.

July 22, 2021
·
3 min read